First, the most significant limitation of this study is the prophylactic administration of the NOX4 inhibitor GKT137831 prior to glycerol or ferrous-myoglobin induction, which contrasts with clinical practice where AKI is an acute, unexpected event requiring intervention post-injury. Here, MB is linked to acute kidney injury.